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Chronic inflammation and fibrosis characterize
Duchenne muscular dystrophy (DMD). We show
that pro-inflammatory macrophages are associated
with fibrosis in mouse and human DMD muscle.
DMD-derived Ly6Cpos macrophages exhibit a profi-
brotic activity by sustaining fibroblast production of
collagen I. This is mediated by the high production
of latent-TGF-b1 due to the higher expression of
LTBP4, for which polymorphisms are associated
with the progression of fibrosis in DMD patients.
Skewing macrophage phenotype via AMPK activa-
tion decreases ltbp4 expression by Ly6Cpos macro-
phages, blunts the production of latent-TGF-b1,
and eventually reduces fibrosis and improves DMD
muscle force. Moreover, fibro-adipogenic progeni-
tors are the main providers of TGF-b-activating en-
zymes in mouse and human DMD, leading to
collagen production by fibroblasts. In vivo pharma-
cological inhibition of TGF-b-activating enzymes
improves the dystrophic phenotype. Thus, an
AMPK-LTBP4 axis in inflammatory macrophages
controls the production of TGF-b1, which is further
activated by and acts on fibroblastic cells, leading
to fibrosis in DMD.INTRODUCTION
Inflammation following tissue damage is essential for the recov-
ery of tissue integrity. Macrophages play pleiotropic roles in both
the inflammatory response and the process of tissue repair that
ensues. These various functions are supported by the different
phenotypes and inflammatory status that macrophages adopt,Cell Repo
This is an open access article under the CC BY-Ndepending on their environment (Wynn and Vannella, 2016). In
many organs, a general picture of macrophage activation was
established during tissue repair after acute injury. Soon after
damage, the tissue is invaded by Ly6Cpos pro-inflammatory
macrophages that support the mounting of the inflammatory
response. Once phagocytosis of tissue and cell debris is
achieved, a second phase of tissue repair occurs, which is char-
acterized by the presence of Ly6Cneg macrophages, exhibiting
anti-inflammatory properties and restorative functions (Cha-
zaud, 2014). The precise phenotype of these anti-inflammatory
macrophages is not well characterized in vivo and likely depends
on the tissue and type of injury. For instance, restorative macro-
phages may depend (in skin) or not (in skeletal muscle) on
interleukin-4 [IL-4] signaling to express the anti-inflammatory
phenotype (Knipper et al., 2015; Varga et al., 2016a). However,
all restorative macrophages exhibit a low expression of pro-
inflammatory effectors and express anti-inflammatory mediators
(IL-10, transforming growth factor b [TGF-b]). Moreover, in all of
the tissues examined so far, Ly6Cneg macrophages that support
tissue repair arise from resident macrophages and/or circulating
Ly6Cpos monocytes that have entered into the tissue and then
are converted into Ly6Cneg macrophages at the time of resolu-
tion of inflammation (Wynn and Vannella, 2016).
In comparison to the acute injury response, the phenotypes
and roles played by macrophages during chronic diseases are
poorly understood. The persistence of tissue injury, whatever
its origin (e.g., toxic, genetic), leads to chronic inflammation
and, most of the time, to the establishment of fibrosis that pro-
gressively replaces the parenchyma. Roles of macrophage sub-
sets in this context are still debated and likely depend on the
tissue and the disease. For instance, alternatively activatedmac-
rophages were shown to promote fibrosis in chronic pancreatitis
(Xue et al., 2015), while similar IL-4/IL-4R (IL-4 receptor)-acti-
vated macrophages reduce fibrosis after helminth infection in
lung and liver (Minutti et al., 2017). In several organs, fibrosis
is induced or aggravated by blood-derived Ly6Cpos macro-
phages (Misharin et al., 2017; Tacke and Zimmermann, 2014).rts 25, 2163–2176, November 20, 2018 ª 2018 The Authors. 2163
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Macrophages have been known for decades to express TGF-b,
which is secreted as a latent protein and must be activated to
signal in target cells, for example, to induce collagen production
by fibroblasts (Biernacka et al., 2011). However, themechanisms
by which macrophages regulate TGF-b secretion have been
overlooked.
Adult skeletal muscle fully regenerates without scarring after
acute injury. During this process, macrophages adopt sequential
pro- then anti-inflammatory phenotypes to exert specific func-
tions toward myogenic precursor cells and to support adult
myogenesis (Arnold et al., 2007; Mounier et al., 2013; Saclier
et al., 2013; Varga et al., 2016b), and toward fibroblastic cells
to prevent excessive matrix deposition (Lemos et al., 2015).
Inversely, in degenerative myopathies, skeletal muscle fails to
regenerate due to permanent and asynchronous cycles of
degeneration-regeneration, such as with mutations of genes en-
coding for proteins of the dystrophin-glycoprotein complex,
which ensures myofiber integrity (Lapidos et al., 2004). In these
disorders, recurrent myofiber damage leads to chronic inflam-
mation and the eventual establishment of fibrosis. Macrophages
are associated with fibrosis in mdx muscle, the mouse model for
Duchenne muscular dystrophy (DMD) (Vidal et al., 2008). Pre-
venting the entry of circulating monocytes into mdx muscle
improves muscle histology and function for several weeks
(Mojumdar et al., 2014; Wehling et al., 2001). Inhibition of the
pro-inflammatory nuclear factor kB (NF-kB) pathway is similarly
associated with a lower macrophage number and a better
phenotype of the muscle (Acharyya et al., 2007). However,
although the presence of several macrophage subsets in dystro-
phic muscle was proposed (Vidal et al., 2008; Villalta et al., 2009,
2011), their precise functions in the establishment of fibrosis
remain uncharacterized.
Here, we show evidence in dystrophic fibroticmuscle of a spe-
cific cellular interplay between Ly6Cpos macrophages and fibro-
blastic cells in which Ly6Cpos macrophages promoted survival
and matrix deposition by fibroblastic cells through the secretion
of TGF-b1. Specifically, Ly6Cpos macrophages secreted high
amounts of latent TGF-b1 due to increased expression of
latent-TGF-b-binding protein (LTBP)4, which is a known gene
modifier in DMD patients (Flanigan et al., 2013). Fibroblastic cells
known as fibro-adipogenic progenitors (FAPs) secreted
increased amounts of enzymes responsible for latent TGF-b acti-
vation. Moreover, the expression of LTBP4 in Ly6Cpos macro-
phages was controlled by AMP kinase (AMPK) activation in
mdx muscle. Cross-talk between inflammatory Ly6Cpos macro-
phages and FAPs leads to increased collagen deposition in
dystrophic muscles that can be pharmacologically controlled
by the regulation of AMPK activity.Figure 1. Macrophages, Fibrosis, and Myogenesis in Human DMD Mu
(A–C) Serial sections of DMD muscles were immunolabeled for macrophages
markers (e.g., CD163, CD206, Arg1, iNOS, TNF-a). Scale bars, 50 mm. Correlati
laminin and Hoechst is blue ).
(B) Spearman correlation wasmade between fibrosis (collagen I area, in percentage
(C) Spearman correlation was made between myogenesis (number of myogeninpo
of (a, a’) total macrophages (CD68pos cells), (b, b’) CD163posCD68pos macroph
phages, (e, e’) iNOSposCD68pos macrophages, and (f, f’) TNFaposCD68pos macro
See also Figures S1 and S2.RESULTS
Macrophages Are the Main Immune Cells Present in
Mouse Degenerative Myopathies and Are Associated
with Fibrosis
Investigation of macrophages was carried out in two murine
models (the dystrophin-deficient mdx and the a-sarcoglycan-
deficient sgca/ mouse strains) of degenerative myopathies
that develop fibrosis with different kinetics. Mdx mice were
used at 8–10 weeks of age—at a stage of chronic disease—
and tibialis anterior muscle was experimentally microinjured
over 2 weeks to induce the establishment of fibrosis after
1 week of rest (fib-mdx) (Desguerre et al., 2012). As shown in Fig-
ure S1A, fib-mdx muscle presented higher irregularity in myo-
fiber shape and size, as compared with mdx muscle, and was
characterized by inflammatory infiltrates and endomysial
fibrosis. sgca/mice develop spontaneous fibrosis at 3 months
(Duclos et al., 1998). At 4 months of age, tibialis anteriormuscles
of sgca/mice exhibited necrosis, inflammatory infiltrates, and
myofibers of various sizes with centrally located nuclei, which re-
flects recent muscle regeneration and endomysial fibrosis (Fig-
ure S1A’). Flow cytometry analysis (Figures S1B and S1B’) of
immune cells showed that in bothmodels, themain cell type pre-
sent in dystrophic fibroticmuscle wasmacrophages, whichwere
increased in number (Figures S1C and S1C’) and represented
73% and 68% of CD45pos cells in fib-mdx and sgca/muscles,
respectively. Among these cells, the Ly6Cneg subset was the
most abundant, accounting for approximately 73%–77% of all
muscle macrophages.
Comparing mdx, fib-mdx, sgca+/ and sgca/ muscles, we
showed that collagen I deposition positively correlated with the
number of fibroblastic cells (platelet-derived growth factor re-
ceptor a-positive [PDGFRapos] cells [Joe et al., 2010; Uezumi
et al., 2010]) (Spearman’s r = 0.796, p < 0.0001) (Figure S2A),
following an sgca+/ < mdx < sgca/ = fib-mdx gradient of
fibrosis, which was also associated with the total number of infil-
trating F4/80pos macrophages in the muscle (Figure S2B).
Myopathic muscles being characterized by a highly heteroge-
neous histological pattern (Rosenberg et al., 2015), we looked
at the distribution of macrophages. Within fib-mdxmuscle, mac-
rophages were not preferentially associated with small or large
myofibers (Figures S2C and S2D); however, the number of mac-
rophages positively correlated with the collagen I area (Figures
S2E and S2F). These results indicate that (1) macrophages
were the main immune cells in dystrophic fibrotic muscle;
(2) the more the muscle was fibrotic, the more macrophages
were numerous; and (3) macrophages specifically associated
with fibrotic areas.scle
(CD68), collagen I, myogenesis markers (eMHC, myogenin), or macrophage
on analyses were done in individual fascicles (line depicted in A, where LM is
of total area) andmyogenesis (number of eMHCpos fibers ormyogeninpos cells).
s cells or eMHCpos fibers, left) or fibrosis (collagen I area, right) and the number
ages, (c, c’) CD206posCD68pos macrophages, (d, d’) Arg1posCD68pos macro-
phages. Results are from 34 fascicles from 6 DMD patients.
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Figure 2. Functions of Macrophage Subsets Isolated from Re-
generating and Dystrophic Muscle toward Fibroblasts
Ly6Cpos and Ly6Cnegmacrophage subsets were sorted from regenerating (left)
and dystrophic (mdx or fib-mdx, right) muscle and were co-cultured with NIH
3T3 fibroblasts.
(A) Luciferase activity as a surrogate of collagen I expression from fibroblasts
previously transfected with a plasmid encoding luciferase under collagen I
promoter.
(B) Fibroblast proliferation (Ki67pos cells).
(C) Fibroblast differentiation into myofibroblasts (a-SMApos cells).
(D) Fibroblast apoptosis (caspase 3pos cells).
Results are means ± SEMs of three (regenerating muscle, left) or four (dystrophic
muscle, right) experiments. *p<0.05, **p<0.01, ***p<0.001usingStudent’s t test.
See also Figure S3.
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Are Associated with Fibrosis in Human DMD and Mouse
Dystrophic Models
Serial sections of human DMD muscles were stained by immu-
nofluorescence for a series of myogenic (embryonic myosin
[eMHC], myogenin), fibrosis (collagen I), and macrophage
markers (CD68 coupled to pro-inflammatory markers such as
inducible nitric oxide synthase [iNOS], tumor necrosis factor a
[TNF-a], or anti-inflammatory markers such as Arg1, CD163,
and CD206), as was previously done for regenerating muscle
(Saclier et al., 2013). Because DMD muscles are highly
heterogeneous, correlation analyses were done in individual
fascicles (example in Figure 1A). Myogenesis did not corre-
late with fibrosis (Figure 1B). The total number of macro-
phages correlated with both the number of myogeninpos cells
(Figure 1C, a) and collagen I area (Figure 1C, a’), indicating
that macrophages were associated with both myogenesis
and fibrosis. As already shown in normal human muscle regen-
eration (Saclier et al., 2013), myogenesis markers (myogenin,
eMHC) positively correlated with anti-inflammatory marker-ex-
pressing macrophages (e.g., CD163, CD206, Arg1; Figure 1C,
b–d), while they were not associated with pro-inflammatory
marker-expressing macrophages (e.g., iNOS, TNF-a; Figure 1C,
e and f). In contrast, collagen I area positively correlated with
only one anti-inflammatory marker (CD163) (Figure 1C, b’–d’).
Moreover, a positive correlation was observed between the
collagen I area and the pro-inflammatory iNOS expressing
macrophages (Figure 1C, e’) and TNF-a expressing cells (Fig-
ure 1C, f’).
These results were confirmed in both fib-mdx and sgca/
muscles. Because only a few markers of macrophage activation
have been developed for cytometry analysis, immunolabeling on
muscle sections was performed for 10 different markers. The
number of F4/80pos macrophages expressing anti-inflammatory
(IL-10, CD206, Dectin 1, CD301, and Arg1) and pro-inflammatory
(TNF-a, C-C chemokine receptor type 2CCR2, Cox2, CCL3, and
iNOS) markers both increased in dystrophic muscle (sgca/,
mdx, fib-mdx) as compared with normal muscle (sgca+/) (Fig-
ures S2G, S2H, and S2I). However, when comparing fibrotic
(sgca/, fib-mdx) to non-fibrotic dystrophic muscle (mdx),
only the number of macrophages expressing pro-inflammatory
markers was increased (with the exception of Arg1 and C-C che-
mokine ligand 3 [CCL3]) (Figures S2G, S2H, and S2I). These re-
sults show that in both human and mouse dystrophic muscle,
fibrosis was associated with pro-inflammatory macrophages.
Ly6Cpos Macrophages Exert Profibrotic Functions
toward Fibroblasts in DMD Muscle
While pro-inflammatory macrophages were associated with
fibrosis in these muscles, Ly6Cneg macrophages were more
numerous than Ly6Cpos macrophages in fibrotic dystrophic
muscle (cf. Figures S1C and S1C’). In post-injury regenerating
muscle, Ly6Cpos macrophages are pro-inflammatory cells at
early steps of regeneration, while Ly6Cneg macrophages exhibit
an anti-inflammatory profile during the later recovery steps of
muscle regeneration (Varga et al., 2016a). qRT-PCR analysis of
the expression of seven genes associated with macrophage
activation inflammatory status indicated that both subsets
(legend on next page)
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expressed both pro- and anti-inflammatory markers (Figures
S3A and S3B). This indicates the presence of a mixed pheno-
type, as previously suggested, because 43% of macrophages
in fib-mdx co-express tnfa and tgfb1 (Lemos et al., 2015).
We therefore focused on the function of macrophage subsets
in fib-mdx muscle. Because fibroblastic cells are the main pro-
vider of collagen in mdx muscle (Pessina et al., 2015) and
because macrophages regulate fibroblastic cell death during
muscle regeneration (Lemos et al., 2015), the effects of Ly6Cpos
and Ly6Cnegmacrophage subsets on fibroblasts were compared
in regenerating and dystrophic fibrotic muscle. Fluorescence-
activated cell sorting (FACS)-sorted FAPs from mdx and fib-
mdx muscle poorly survive and poorly grow in short-term
(2 days) culture, although surviving cells expand after 4–5 days
of culture. However, properties of macrophages must be tested
shortly after their sorting (i.e., 24 hr) because they rapidly adapt
or alter their inflammatory phenotype to their novel environment.
Therefore, long-term FAP culture is not compatible with short-
term macrophage analysis. Consequently, we used fibroblastic
cells (NIH 3T3) as a surrogate of FAPs. In regenerating muscle,
only the Ly6Cneg macrophage subset stimulated the expression
of a collagen I reporter gene transfected into fibroblasts (+200%
at D2 and +60% at D4 post-injury) (Figures S3C and 2A), in
accordance with previous results obtained with FAPs (Lemos
et al., 2015). Conversely, in both sgca/ and fib-mdx muscles,
only Ly6Cpos macrophages increased collagen production by fi-
broblasts by 208% and 309%, respectively (Figures S3C and
2A). Furthermore, proliferation and differentiation of fibroblasts
was decreased by Ly6Cpos macrophages that issued from re-
generating muscle (Figures 2B and 2C), while inversely, Ly6Cpos
isolated from fib-mdx muscle stimulated the differentiation of fi-
broblasts into a-smooth muscle actin-positive (a-SMApos) cells
(Figure 2C). It is worth mentioning that in mdx, both subsets
increased the number of a-SMApos fibroblasts (Figure 2C).
Finally, we showed that Ly6Cpos macrophages from regenerat-
ing muscle induced fibroblast apoptosis, as it was shown for
FAPs (Lemos et al., 2015), and that Ly6Cposmacrophages issued
from fib-mdx lost this property and even protected fibroblasts
from death (Figure 2D). These results show that in fibrotic dystro-
phic muscle, Ly6Cpos macrophages favored fibroblast persis-
tence and their production of collagen I, thus contributing to
the establishment of fibrosis.
TGF-b1 Controls the Profibrogenic Properties of
Ly6Cpos Macrophages in Dystrophic Skeletal Muscle
As in various other tissues, TGF-b1 has been involved in the
establishment of fibrosis in skeletal muscle, particularly in DMDFigure 3. Latent TGF-b1 Is Secreted by Profibrotic Ly6Cpos Macrophag
(A) Area of TGF-b1 immunolabeling on mdx or fib-mdx muscle sections.
(B) Mean fluorescence intensity (MFI) of TGF-b1 immunolabeling in F4/80pos cells
(C) TGF-b1 production of macrophage subsets sorted from regenerating (day 1 aft
24 hr of culture.
(D and E) Macrophage subsets sorted from fib-mdx muscle were co-cultured wi
(D) The number of apoptotic fibroblasts was assessed after caspase 3 immunola
(E) Luciferase activity was measured as a reporter for collagen I expression, as i
(F) TGF-b1 production of BMDMs stimulated for 3 days with various cytokines o
Results aremeans ±SEMs of three (A and E), four (B and F), six (C), and five (D) exp
by the bars or versus no cytokine in (F). *p < 0.05, **p < 0.01, ***p < 0.001; versu
2168 Cell Reports 25, 2163–2176, November 20, 2018(Andreetta et al., 2006; Chen et al., 2005; Vetrone et al., 2009;
Vidal et al., 2008). TGF-b1 is secreted in the milieu as a single
latent molecule comprising an N-terminal latency-associated
peptide and the C-terminal mature TGF-b, which dimerizes
and complexes with latent TGF-b binding protein (LTBP) to be
secreted and to interact with the extracellular matrix (Travis
and Sheppard, 2014). Figure 3A shows that TGF-b1 protein level
(as the staining area on the muscle tissue section) was increased
2.6-fold in fib-mdx as comparedwithmdxmuscle. Measurement
of tgfb1 mRNA showed no difference between Ly6Cpos and
Ly6Cneg macrophages that issued from regenerating, mdx, or
fib-mdx muscle (Figure S3B). However, macrophages ex-
pressed TGF-b1 in dystrophic muscle as assessed by F4/80
and TGF-b1 co-staining (Figure 3B). Moreover, TGF-b1 mean
fluorescence intensity (MFI) of macrophages was increased by
15% in fib-mdx as compared with mdx muscle (Figure 3B).
More precisely, ELISA measurement of TGF-b1 secreted by
sorted macrophages showed that Ly6Cneg macrophages from
regenerating muscle produced 10-fold more TGF-b1 than their
Ly6Cpos counterpart (Figure 3C). Conversely, Ly6Cpos macro-
phages isolated from fib-mdx muscle secreted 6.3-fold more
TGF-b1 than Ly6Cneg macrophages in fib-mdx (Figure 3C) (and
3.5- and 34-fold more than Ly6Cneg and Ly6Cpos macrophages
from regenerating muscle), in accordance with their stimulating
effect on fibroblasts (see Figure 2). In both conditions, TGF-b1
wasmainly secreted in a latent form (Figure 3C). In co-culture ex-
periments of macrophages isolated from fib-mdx with fibro-
blasts, blocking anti-TGF-b1 antibodies abolished the protective
effect of Ly6Cpos macrophages on fibroblast apoptosis (Fig-
ure 3D) and blunted the stimulation of collagen I expression by
Ly6Cposmacrophages (Figure 3E). Finally, to investigate whether
the dystrophic environment affects naive unactivated macro-
phages, bone marrow-derived macrophages (BMDMs) were
treated with protein homogenate from fib-mdx muscle or with
IL-4, which is a well-known inducer of TGF-b1 production in
macrophages. Fib-mdx muscle homogenate triggered TGF-b1
secretion as efficiently as IL-4 did (Figure 3F). These results indi-
cate that the fib-mdx muscle environment stimulated Ly6Cpos
macrophages to secrete high amounts of latent TGF-b1, which
directly acted on fibroblastic cells to promote fibrosis.
LTBP4 Controls Latent TGF-b1 Secretion by Ly6Cpos
Macrophages in fib-mdx
Latent TGF-b is secreted when complexed to LTBP (Travis and
Sheppard, 2014). Among the murine LTBPs, LTBP4 was ex-
pressed by macrophages in skeletal muscle, with an increased
expression by Ly6Cpos macrophages in fibrotic dystrophices in fib-mdx
relative to TGF-b1MFI in the whole picture on mdx or fib-mdx muscle sections.
er injury for Ly6Cpos cells; day 4 for Ly6Cneg cells) or from fib-mdxmuscles after
th fibroblasts, as in Figure 2, with or without TGF-b1-blocking antibodies.
beling.
n Figure 2A.
r with total protein extracts from fib-mdx muscle.
eriments. The Student’s t test was performed between the conditions indicated
s all other conditions in C, ###p < 0.001. Scale bar, 50 mm.
Figure 4. Latent TGF-b1 Secretion by Ly6Cpos Macrophages Is
Regulated by LTBP4
(A) Macrophage subsets were sorted from regenerating (day 1 after injury for
Ly6Cpos cells; day 4 for Ly6Cneg cells) mdx or fib-mdx muscles, and the ltbp4
mRNA level was analyzed by qRT-PCR. NRQ, normalized relative quantity.muscle (Figure 4A). LTBP4 was shown to be a gene modifier in
mdx, sarcoglycanopathies, and DMD patients, where it is asso-
ciated with fibrogenesis (Flanigan et al., 2013; Heydemann et al.,
2009). The expression of LTBP4 by F4/80pos macrophages in fib-
mdx muscle was confirmed at the protein level by immunofluo-
rescence. Confocal analysis showed that macrophages ex-
pressed both LTBP4 and TGF-b1 in fib-mdx muscle (Figures
4B and S4A). Most (92.5%) of the LTBP4pos cells were F4/
80pos cells. Thus, at the protein level, 7.5% of LTBP4-expressing
cells were not macrophages and were possibly fibroblasts.
qRT-PCR analysis on FACS-isolated populations indicated
that FAPs expressed 800-fold more ltbp4 mRNA than macro-
phages (Figure S4B). Given that LTBP4 is synthesized as a
short or long form under the control of two independent pro-
moters (Kantola et al., 2010), that the long form alone was barely
detectable in macrophages, while its expression accounted for
12% of the total ltbp4 mRNA in FAPs (Figure S4B), and that
the antibodies raised against LTBP4 recognize both forms of
the protein, we cannot explain the discrepancy between high
mRNA and low protein amounts of LTBP4 in FAPs. Thus, we
cannot exclude that a LTBP4-latent TGF-b interaction controls
TGF-b1 secretion in other cell types such as fibroblastic cells.
However, given that LTBPs and TGF-b1 assemble together in-
side the cell before being secreted in the milieu as a complex
(Robertson et al., 2015; Miyazono et al., 1991), only macro-
phage-derived LTBP4 can control the latency of macrophage-
derived TGF-b1.
Three different small interfering RNAs (siRNAs) were used to
inhibit ltbp4 expression in BMDMs from 43% to 56% (Figure 4C).
BMDMs treated with fib-mdx muscle homogenates as above
(Figure 3D) showed a strongly reduced TGF-b1 secretion when
ltbp4 was silenced (56%–76% inhibition) (Figure 4D). These re-
sults indicate that the DMD gene modifier ltbp4 controlled
TGF-b1 secretion in Ly6Cpos macrophages in fibrotic muscle.
AMPK Activation Blunts LTBP4 Expression and Latent
TGF-b1 Secretion by Ly6Cpos Macrophages in fib-mdx
During skeletal muscle regeneration, the transition from pro-in-
flammatory Ly6Cpos macrophages to recovery LyC6neg macro-
phages is controlled by AMPKa1 activation (Mounier et al.,
2013).We therefore investigated whether AMPK activation acted
on the LTBP4/TGF-b1 axis in macrophages. We investigated
in vitro the effects of AMPK activation on BMDMs rendered pro-
fibrotic by treatment with fib-mdx muscle homogenates (as in
Figure 3F). We showed that AMPK activation by metformin, an
antidiabetic compound known to activate AMPK (Foretz et al.,(B) Confocal analysis (z stack increments of 0.5 mm) of sections of fib-mdx
muscles immunolabeled for F4/80 (red), LTBP4 (green), and TGF-b1 (gray);
Hoechst (blue). z Stacks are represented for XZ and YZ views along the yellow
lines. Scale bar, 50 mm.
(C and D) BMDMs were transfected with three different siRNAs directed
against ltbp4 or with a control siRNA (siScr) and were incubated for 3 days with
a fib-mdx muscle extract. (C) Ltbp4 mRNA level was measured by qRT-PCR
and (D) TGF-b1 production was quantitated by ELISA.
Results are means ± SEMs of six (A) and four (C and D) experiments. *p < 0.05,
**p < 0.01, ***p < 0.001 between the indicated bars or versus siScr in (C)
and (D).
See also Figure S4.
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Figure 5. AMPKa1 Activation Regulates Latent TGF-b1 Secretion through the Control of ltbp4 Expression in Macrophages
(A andB) BMDMswere incubated for 3 days with a fib-mdxmuscle extract, and DMSO, 991, ormetformin (MET) was added for the last 20 hr. (A) Ltbp4 expression
was measured by qRT-PCR and (B) TGF-b1 production was quantitated by ELISA.
(C) Design of metformin treatment of fib-mdx mice for experiments presented in (D)–(L).
(D) Ltbp4 expression in macrophage subsets sorted from muscles of treated and non-treated mice was determined by qRT-PCR.
(E) TGF-b1 production by macrophages sorted, as in (D).
(F) Area of TGF-b1 immunolabeling on muscle sections.
(G–K) Histological analysis of muscle sections of treated (MET) and untreated (H2O) fib-mdx mice.
(G) Number of macrophages (as F4/80pos cells) per fiber.
(H) Percentage of macrophages (as F4/80pos cells) expressing pro- (TNF-a, iNOS) or anti-inflammatory markers (CD301, CD206, Arg1).
(I) Area of necrosis.
(J) Area of collagen I.
(K) Myofiber CSA mean (left graph) and distribution (right graph).
(legend continued on next page)
2170 Cell Reports 25, 2163–2176, November 20, 2018
2014), or by its specific activator 991 (Guigas and Viollet, 2016),
strongly reduced ltbp4 expression by BMDMs treated by fib-
mdx muscle homogenates (68% and 61%, respectively) (Fig-
ure 5A). In the same conditions, TGF-b1 production by macro-
phages was strongly reduced upon AMPK activation (58% and
37%, respectively) (Figure 5B). To confirm this circuit of regula-
tion in vivo, and since specific activation of AMPK in vivo with
991 is not viable, fib-mdx mice were treated with metformin dur-
ing fibrosis establishment (Figure 5C). Ly6Cpos macrophages
isolated from these muscles exhibited a strong decrease (68%)
in ltbp4 expression (Figure 5D), associated with a reduction
in their TGF-b1 production (55%) (Figure 5E) (note that the
weak secretion of active TGF-b1 was also completely blunted
upon metformin treatment). Consequently, metformin treatment
induced a 25% decrease in TGF-b1 staining in the muscle (Fig-
ure 5F), while the number of macrophages did not change (Fig-
ure 5G). However, their expression of pro-inflammatory marker
TNF-a was decreased and that of anti-inflammatory CD206
(+15%) and CD301 (+41%) markers was increased (Figure 5H).
Furthermore, we observed a decrease in the necrotic (56%)
(Figure 5I) and fibrotic (23%) (Figure 5J) areas in the muscle
of the treated animals, together with an increased cross-
sectional area (CSA) of the regenerating myofibers (+38%) (Fig-
ure 5K), partly due to an increase in the number of myonuclei/
myofibers (Figure S5A). Accordingly, the number of Pax7pos cells
was decreased upon metformin treatment (Figure S5B), in
accordance with a decrease in their self-renewal upon AMPK
activation (Theret et al., 2017). Finally, we measured the force
produced by the tibialis anterior (TA) in these conditions and
showed that both absolute and specific isometric force produc-
tions were increased in metformin-treated animals (+21%
and +22%, respectively) (Figure 5L).
These results show that activation of AMPK dampened ltbp4
expression by pro-inflammatory macrophages and, conse-
quently, their production of TGF-b1 in themilieu. Therefore, stim-
ulating the shift of pro-inflammatory macrophages toward an
anti-inflammatory status is associated with a decrease in fibrosis
and an improvement in the muscle in DMD.
Activation of Latent TGF-b1 by FAPs Promotes Fibrosis
in fib-mdx
Latent TGF-b1 can be activated by a series of molecules,
including enzymes and anchoring proteins such as integrins
(Travis and Sheppard, 2014). We isolated FAPs from regenerat-
ing, mdx, and fib-mdx muscle and identified that FAPs from
fib-mdx exhibited an increased expression of a series of latent
TGF-b activators (Figure 6A). Both matrix metalloproteinase
(mmp) 14 and bone morphogenetic protein (bmp) 1 were almost
exclusively expressed by FAPs and only weakly by the other cell
types in fib-mdx muscle (Figure 6B) (gating strategy is shown in
Figures S6A and S6B). These results suggest that FAPs were the
main producers of BMP1 and MMP14 to activate latent TGF-b1
previously secreted by Ly6Cpos macrophages to promote(L) Absolute and specific force measured on TA of fib-mdx and metformin-treate
Results are means ± SEMs of three (A), five (B and G–K), four (D–F), and five (L) ex
indicated bars or versus +DMSO in (A) and (B) or versus H2O in (K) and (L).
See also Figure S5.fibrosis. Expression of both BMP1 and MMP14 by PDGFRapos
cells (i.e., FAPs) (Lemos et al., 2015) was confirmed at the protein
level in fib-mdx muscle (Figure 6C). In humans, bmp1 and
mmp14 were highly expressed by fibroblasts issued from DMD
muscle as compared with normal muscle (Figure 6D). Seven-
day cultured FAPs did express much lower levels of bmp1 and
mmp14 than freshly isolated FAPs, indicating that long-term cul-
ture of the cells altered some of their properties (Figure S6C). To
confirm the functional role of MMP14 and BMP1 produced by
fibroblastic cells in the activation of latent TGF-b1, siRNAs
were co-transfected in fibroblasts with a collagen I-LUC reporter
gene. Fibroblastic mmp14 or bmp1 knockdown (Figure 6E)
decreased the stimulation of collagen I expression triggered by
Ly6Cpos macrophages (Figure 6F), demonstrating that these en-
zymes participated in the activation of latent TGF-b1 produced
by fibrotic macrophages. Finally, we treated fib-mdx mice with
specific pharmacological inhibitors of MMP14 and BMP1 activ-
ities (NSC-405020 and UK-383367, respectively) (Bailey et al.,
2008; Zarrabi et al., 2011) and showed a significant improvement
in themuscle, including reduction in necrosis (60% and57%,
respectively) (Figure 6G), reduction in fibrosis (11% and 8%,
respectively) (Figure 6H), and increase in myofiber CSA mean
(+20% and +24% respectively, data not shown), and a myofiber
CSA distribution shift to larger myofibers (Figure 6I).
DISCUSSION
In the present study, we identified a molecular mechanism of
fibrosis establishment in DMD by macrophages. In contrast to
their anti-fibroblastic role during skeletal muscle regeneration
following acute injury, Ly6Cpos macrophages exerted pro-
fibrotic activities in dystrophic muscle. These inflammatory mac-
rophages secreted high amounts of latent TGF-b1 due to a high
expression of LTBP4, which allows its secretion into the milieu.
LTBP4 has been shown to be a gene modifier in DMD patients
(Flanigan et al., 2013), and we show here that its expression
was controlled by AMPK activation. Consequently, pharmaco-
logical activation of AMPK improved the dystrophic muscle.
Moreover, latent TGF-b1 was activated by FAPs through a series
of enzymes; among these were BMP1 and MMP14, whose spe-
cific pharmacological inhibition was also associated with an
improvement of dystrophic muscle.
The inflammatory status of macrophages that are responsible
for fibrosis is still a matter of debate. Some studies show that
anti-inflammatory and alternatively activated macrophages are
responsible for fibrosis (Redente et al., 2014; Xue et al., 2015).
However, other analyses indicate that CCR2pos or Ly6Cpos
macrophages drive fibrosis establishment (Baeck et al., 2014;
Lebrun et al., 2017), suggesting that depending on the tissue
and disease considered, specific macrophage subsets may be
involved. In dystrophic skeletal muscle, several studies have
implicated macrophages and fibrosis (Vidal et al., 2008; Wehling
et al., 2001). However, the role of macrophage-derived TGF-b1d fib-mdx mice. NRQ, normalized relative quantity.
periments. *p < 0.05, **p < 0.01, ***p < 0.001 using Student’s t test between the
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has not been addressed, nor has the type of macrophage subset
driving fibrosis. Our histological analysis clearly indicates in both
murine and human DMD muscle that macrophages expressing
pro-inflammatory markers were associated with fibrosis, while,
as expected (Arnold et al., 2007; Saclier et al., 2013), areaswhere
myogenesis took place were associated with macrophages ex-
pressing anti-inflammatory effectors. These results are in accor-
dance with the beneficial effect on diaphragm fibrosis observed
in Toll-like receptor 4 (TLR4)-deficient mdx mice in which pro-in-
flammatory macrophages are reduced (Giordano et al., 2015).
Functionally, Ly6Cpos macrophages exerted the opposite effect
in regenerating muscle and in fib-mdx. In regenerating muscle,
Ly6Cpos macrophages inhibited proliferation and differentiation
of fibroblasts, and induced their apoptosis, as was previously
shown for FAPs (Lemos et al., 2015). Inversely, in fib-mdx,
Ly6Cposmacrophages promoted the differentiation of fibroblasts
along with their production of collagen I, and protected them
from apoptosis. The latter two properties were blunted by inhib-
iting TGF-b1 in the co-culture, indicating the requirement of the
profibrotic cytokine in this process. While the secretion of
TGF-b1 by macrophages has been known for a long time from
seminal in vitro and ex vivo studies (Assoian et al., 1987; Groten-
dorst et al., 1989; Khalil et al., 1996), the secretion of TGF-b1 pro-
tein by tissue-derived macrophages has been only rarely directly
documented (Harel-Adar et al., 2011). The mechanisms regu-
lating tgfb1 gene expression by macrophages are poorly known,
the best characterized being phagocytosis of apoptotic and/or
necrotic cells via the phosphatidylserine receptor, which triggers
TGF-b1 synthesis (Huynh et al., 2002). Of note, qRT-PCR anal-
ysis of sorted Ly6Cpos and Ly6Cneg macrophage populations
indicated no difference in tgfb1 gene expression, suggesting
post-transcriptional regulation to explain different TGF-b1 pro-
duction by the two populations.
Latent TGF-b1 is secreted from cells within a complex, where
it is associated with latent associated peptide (LAP) and LTBP
(Miyazono et al., 1991; Robertson et al., 2015). In LTBP4-defi-
cient mice, secretion of TGF-b1 is inhibited, preventing lung
fibrosis (Zhou et al., 2009). We showed that in fib-mdx, Ly6Cpos
macrophages expressed higher levels of ltbp4 in and that
controlled their TGF-b1 secretion, providing a molecular mecha-
nism sustaining the profibrotic activity of Ly6Cpos macrophagesFigure 6. FAPs Express High Levels of Latent TGF-b Activating Protea
(A) FAPs were sorted from regenerating (day 1 or 4 after injury) or mdx or fib-mdx
TGF-b was measured by qRT-PCR.
(B) Neutrophils (Neut), Ly6Cneg macrophages (MP Ly6Cneg), Ly6Cpos macrophage
from fib-mdx muscles, and the mRNA levels of mmp14, bmp1, and pdgfra were
(C) fib-mdx muscle sections were immunolabeled for MMP14 or BMP1 (green) an
BMP1. Scale bar, 50 mm.
(D) The mRNA level of several genes coding for activators of latent TGF-b was me
(NM) or DMD patient muscle.
(E) NIH 3T3 cells were co-transfected with siRNAs directed against mmp14 or bm
(left graph), and bmp1 (right graph) mRNA level was measured by qRT-PCR. siC
(F) Fibroblasts were transfected as in (E) and were co-cultured with Ly6Cpos ma
determined. Each color stands for one experiment.
(G–I) fib-mdx mice were treated with pharmacological inhibitors of MMP14 (NSC
distribution of myofiber CSA (I) were evaluated.
Results are means ± SEMs of three (A, and NM in D), eight (DMD in D), five (E), fou
Student’s t test.
See also Figure S6.in muscular dystrophy. LTBP4 is identified as a gene modifier in
muscular dystrophies and in DMD patients, specific polymor-
phisms being associated with different levels of the TGF-b
signaling pathway and fibrosis establishment due to differential
binding to TGF-b1 and cleavage sensitivity (Flanigan et al.,
2013; Heydemann et al., 2009; Lamar et al., 2016).
AMPKa1 is required for the resolution of inflammation and the
acquisition of the anti-inflammatory phenotype by macrophages
during normal muscle regeneration (Mounier et al., 2013). In vitro
specific AMPK activation (by 991) in macrophages triggered the
downregulation of ltbp4 expression, which in turn led to a
decreased TGF-b1 secretion by these cells. Although AMPK
likely controls ltbp4 expression indirectly, our data show the
regulation of TGF-b1 secretion by AMPK activation. As a conse-
quence, in vivo pharmacological activation of AMPK by metfor-
min led to an improvement of the dystrophic phenotype,
including at the functional level. Although metformin has
AMPK-independent properties, improvement of the muscle
was associated with a decrease in the pro-inflammatory status
and an increase in the anti-inflammatory status of macrophages.
Under these conditions, we showed that Ly6Cpos macrophages
specifically expressed lower levels of ltbp4 and secreted lower
amounts of TGF-b1 in vivo. While AMPK activation was shown
to reduce fibrosis in several diseases (Jiang et al., 2017) and to
improve dystrophic muscle (Ljubicic et al., 2011; Pauly et al.,
2012), our data provide evidence of an AMPK-controlled
TGF-b1 production by macrophages that can be alleviated
through systemic AMPK activation.
Once in the milieu, latent TGF-b1 must be activated to exert its
properties and bind to its receptors (Travis and Sheppard, 2014).
Activation is made by both enzymatic and mechanical mecha-
nisms. We found that, in fibrotic muscle, FAPs were the main
source of TGF-b-activating enzymes, among which MP1 and
MMP14, that were also overexpressed by human fibroblasts iso-
lated from human DMD muscle. FACS-sorted FAPs from fib-
mdx muscle grew very poorly in culture, however, in contrast
to FAPs sorted from non-dystrophic regenerating muscle. This
limitation prevented the analysis of their secretion of TGF-b1,
as well as their co-culture with macrophages. Nevertheless, we
showed that silencing mmp14 or bmp1 in fibroblasts prevented
the activation of TGF-b1, and therefore the production ofses
muscles, and the mRNA level of various genes coding for activators of latent
s (MP Ly6Cpos), satellite cells (SC), endothelial cells (EC), and FAPs were sorted
measured by qRT-PCR.
d PDGFRa (red); Hoechst (blue). Arrows indicate FAPs expressing MMP14 or
asured by qRT-PCR in primary human fibroblasts derived from normal muscle
p1 with a plasmid encoding luciferase under collagen I promoter and mmp14
TL, control using a non-specific siRNA.
crophages sorted from fib-mdx muscle for 20 hr, and luciferase activity was
) or of BMP1 (UK) for 3 weeks. The necrosis area (G), collagen I area (H), and
r (F), and six (G, H, and I) experiments. *p < 0.05, **p < 0.01, ***p < 0.001 using
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collagen I when they were co-cultured with Ly6Cpos macro-
phages. Moreover, pharmacological inhibition of either BMP1
or MMP14 improved the fib-mdx phenotype and reduced
fibrosis in fib-mdx muscle.
To conclude, the present study evidenced an Ly6Cpos profi-
brotic macrophage subpopulation in dystrophic muscle that ex-
erts its functions by actively producing latent TGF-b1 thanks to
the synthesis of LTBP4, which controls its secretion. Latent
TGF-b1 is then activated by enzymes produced by FAPs, and
the active TGF-b1 acts in turn on FAPs and fibroblastic cells to
promote fibrosis (production of collagen I, differentiation into
myofibroblasts, protection from apoptosis). Macrophage ltbp4
expression is reduced by the activation of AMPKa1. Accordingly,
this macrophage-FAP fibrotic circuit may be blunted by pharma-
cological treatments targeting either the production of TGF-b1
by macrophages (via activation of AMPK) or the enzymatic acti-
vation of TGF-b1 by FAPs (via inhibition of BMP1 or MMP14),
both of which improve dystrophic muscle by reducing necrosis
and fibrosis, increasing the size of regenerating myofibers, and
increasing muscle strength.STAR+METHODS
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Antibodies
Rat monoclonal anti-F4/80 (clone CI:A3-1) Abcam Cat# ab6640; RRID:AB_1140040
Rat monoclonal anti-F4/80 Abcam Cat# ab74383; RRID:AB_1860121
Goat polyclonal anti-Arg1 Santa Cruz Biotechnology Cat# sc-18355; RRID:AB_2058957
Rabbit polyclonal anti-CCL3 Abcam Cat# ab32609; RRID:AB_776125
Rabbit monoclonal anti-CCR2 (clone E68) Abcam Cat# ab32144; RRID:AB_1603737
Rat monoclonal anti-CD206 (clone MR5D3) Santa Cruz Biotechnology Cat# sc-58987; RRID:AB_2144905
Rat monoclonal anti-CD301 (clone ER-MP23), Abcam Cat# ab59167; RRID:AB_941058
Rabbit polyclonal anti-Collagen I Abcam Cat# ab292; RRID:AB_303415
Rabbit polyclonal anti-Collagen I Abcam Cat# ab34710; RRID:AB_731684
Goat polyclonal anti-Collagen I Southern Biotech Cat# 1310-01
Goat polyclonal anti-Cox2 (ab23672), Abcam Cat# ab23672; RRID:AB_731725
Rat monoclonal anti-Dectin 1 (clone 2A11), Abcam Cat# ab53427; RRID:AB_2040609
Rabbit polyclonal anti-IL-10 Abcam Cat# ab9969; RRID:AB_308826
Rabbit polyclonal anti-iNOS Abcam Cat# ab15323; RRID:AB_301857
Rabbit polyclonal anti-BMP1 Abcam Cat# ab118520; RRID:AB_10899275
Rat monoclonal anti-Laminin (clone AL-1), Abcam Cat# ab78287; RRID:AB_1604106
Rabbit polyclonal anti-Laminin Sigma-Aldrich Cat# L9393; RRID:AB_477163
Goat polyclonal anti-PDGFRa R&D Systems Cat# AF1062; RRID:AB_2236897
Rabbit polyclonal anti-TNFa Abcam Cat# ab34839; RRID:AB_778527
Rabbit polyclonal anti-LTBP4 Santa Cruz Biotechnology Cat# sc-33144; RRID:AB_2139064
Rabbit monoclonal anti-MMP14 (clone EP1264Y) Abcam Cat# ab51074; RRID:AB_881234
Donkey anti-rat IgG (H+L), Cy3-conjugated Jackson ImmunoResearch Cat# 712-165-153; RRID:AB_2340667
Donkey anti-rabbit IgG (H+L), Cy3-conjugated Jackson ImmunoResearch Cat# 711-165-152; RRID:AB_2307443
Donkey anti-rabbit IgG (H+L), FITC-conjugated Jackson ImmunoResearch Cat# 711-095-152; RRID:AB_2315776
Donkey anti-goat IgG (H+L), Cy3-conjugated Jackson ImmunoResearch Cat# 705-165-147; RRID:AB_2307351
Donkey anti-goat IgG (H+L), FITC-conjugated Jackson ImmunoResearch Cat# 705-095-147; RRID:AB_2340401
Donkey anti-mouse IgG (H+L), Cy3-conjugated Jackson ImmunoResearch Cat# 715-165-150; RRID:AB_2340813
Donkey anti-mouse IgG (H+L), FITC-conjugated Jackson ImmunoResearch Cat# 715-095-150; RRID:AB_2340792
Donkey anti-mouse IgG (H+L), DyLight649-conjugated Jackson ImmunoResearch Cat# 715-495-150
Mouse monoclonal anti-CD68 (Clone KP1), Abcam Cat# ab955; RRID:AB_307338
Mouse monoclonal anti-Myogenin DSHB Cat# F5D; RRID:AB_528355
Mouse monoclonal anti-eMHC DSHB Cat# F1.652; RRID:AB_528358
Rat monoclonal anti-mouse CD16/CD32 (clone 2.4G2) BD Biosciences Cat# 553142; RRID:AB_394657
Rat monoclonal anti-Ly6C/G (clone RB6-8C5),
APC-conjugated
Thermo Fisher Scientific Cat# 17-5931-82; RRID:AB_469476
Mouse monoclonal anti-CD64 (Clone X54-5/7.1),
AF647-conjugated
BD Biosciences Cat# 558539; RRID:AB_647120
Rat monoclonal anti-F4/80 (clone BM8), PE-conjugated Thermo Fisher Scientific Cat# 12-4801-82; RRID:AB_465923
Rat monoclonal anti-CD45 (clone 30-F11), PE-Cy7-
conjugated
Thermo Fisher Scientific Cat# 25-0451-82; RRID:AB_2734986
Rat monoclonal anti-Ly6C (clone HK1.4), APC-conjugated Thermo Fisher Scientific Cat# 17-5932-82; RRID:AB_1724153
Rat monoclonal anti-Sca-1 (clone D7), PerCP-Cy5.5-
conjugated
Thermo Fisher Scientific Cat# 45-5981-82; RRID:AB_914372
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Rat monoclonal anti-a7-integrin (clone R2F2), AF647-
conjugated
AbLab Cat# 67-0010-05
Rat monoclonal anti-CD31 (clone 390), PE-conjugated Thermo Fisher Scientific Cat# 12-0311-82; RRID:AB_465632
Rat monoclonal anti-CD34 (clone RAM34), FITC-
conjugated
Thermo Fisher Scientific Cat# 11-0341-82; RRID:AB_465021
Mouse monoclonal anti-a-SMA (clone 1A4) Sigma-Aldrich Cat# A5228; RRID:AB_262054
Rabbit polyclonal anti-Ki67 Abcam Cat# ab15580; RRID:AB_443209
Rabbit polyclonal anti-active Caspase 3 Abcam Cat# ab13847; RRID:AB_443014
Mouse monoclonal blocking anti-TGFb1 (clone 2Ar2) Abcam Cat# ab64715; RRID:AB_1144265
Biological Samples
Fibroblasts from human muscle Cochin Hospital Cell Bank, Paris,
agreement no. DC-2009-944
(Desguerre et al., 2009 PMID
19535995).
N/A
Human muscle biopsies (Desguerre et al., 2009 PMID
19535995)
N/A
Chemicals, Peptides, and Recombinant Proteins
Compound 991 SpiroChem CAS:129739-36-2
Cardiotoxin from Naja pallida Latoxan Cat# L8102
Collagenase B Roche Diagnostics GmbH Cat# 11088831001
Dispase II Roche Diagnostics GmbH Cat# 04942078001
DMEM/F-12 medium, Glutamax Supplement GIBCO Cat# 31331028
DMEM, high glucose, Glutamax Supplement, pyruvate GIBCO Cat# 31966021
DMSO Sigma-Aldrich Cat# D2650; CAS:67-68-5
Fetal Bovine Serum (FBS) GIBCO Cat# 10270106
jetPRIME Polyplus transfection Cat# 114-01
LightCycler 480 SYBR Green I Master Roche Diagnostics Cat# 04887352001
Lipofectamine 2000 Invitrogen Cat# 11668500
Metformin hydrochloride Sigma-Aldrich Cat# PHR1084; CAS:1115-70-4
NSC-405020 MedChemExpress Cat# HY-15827; CAS:7497-07-6
Recombinant Mouse IFNg R&D Systems Cat# 485-MI-100; GenPept: P01580
Recombinant Mouse IL4 R&D Systems Cat# 404-ML-010 ; Genpept: P07750
RNeasy Plus Micro kit QIAGEN Cat# 74034
TRIzol Reagent Life Technologies Cat# 15596018
UK-383367 Sigma-Aldrich Cat# PZ0156; CAS:348622-88-8
Critical Commercial Assays
Dual-Glo Luciferase Assay System Promega Cat# E2920
TGF beta-1 Human/Mouse Uncoated ELISA Kit Thermo Fisher Scientific Cat# 88-8350-22
Experimental Models: Cell Lines
NIH 3T3 cell line ECACC Cat# 93061524; RRID: CVCL_0594
L929 cell line ECACC Cat# 85011425; RRID: CVCL_0462
Experimental Models: Organisms/Strains
Mouse C57BL/6J Jaxmice Cat# 000664; RRID_IMSR_JAX:000664
Mouse CX3CR1GFP/+ (Cx3cr1tm1Litt/+). Mice were
backcrossed for ten generations to C57BL/6 mice as
described in Geissman et al., 2003 (PMID:12871640)
TAAM Orleans, CNRS RRID:MGI:4833984
Mouse mdx (Dmdmdx-4cv/Dmdmdx-4cv) Jaxmice Cat# 002378 RRID:MGI:3798618
Mouse sgca/ (Sgcatm1Kcam/ Sgcatm1Kcam). Mice were
backcrossed for ten generations to C57BL/6 mice .
MGI RRID:MGI:2176866
(Continued on next page)
e2 Cell Reports 25, 2163–2176.e1–e6, November 20, 2018
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
AllStars Negative Control siRNA QIAGEN Cat# 1027280
Ltbp4 siRNA#1 (Mm_Ltbp4_4); QIAGEN Cat# SI 00244160
Ltbp4 siRNA#2 (Mm_Ltbp4_7); QIAGEN Cat# SI 02748095
Ltbp4 siRNA#3 (Mm_Ltbp4_8); QIAGEN Cat# SI 04942623
Mmp14 siRNA#5 (Mm_Mmp14_5); QIAGEN Cat# SI 02687713
Bmp1 siRNA#5 (Mm_Bmp1_5); QIAGEN Cat# SI 02669457
Primers (cf. Table S2) Eurogentec N/A
Recombinant DNA
pGL3-Basic control plasmid Promega Cat# E1751
pGl3-Collagen I plasmid Peter Mertens, Otto-von-
Guericke-Universita¨t
Magdeburg, Germany
N/A
pRL-TK Renilla Luciferase Control Reporter Vector Promega Cat# E2241
Software and Algorithms
ImageJ Schneider et al., 2012; PMID:
22930834
https://imagej.net/Welcome
GraphPad Prism GraphPad Software https://www.graphpad.com/scientific-
software/prism/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Be´ne´dicte Chazaud
(benedicte.chazaud@inserm.fr).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6, CX3CR1GFP/+, mdx, mdx;CX3CR1GFP/+, sgca+/, sgca/, sgca+/;CX3CR1GFP/+ and sgca/;CX3CR1GFP/+ mice were
bred and used according to French and European regulations. The protocols have been approved by the Ethical committee from
Universite´ Paris Descartes (CEEA34.BC-RM.053.12) and from Universite´ Claude Bernard Lyon 1 (CEEA55 APAFIS#5871-
2016062912432608 v2). Experiments were conducted onmales at 8-10weeks of age for mdx and 16-18weeks of age for sgca. Mus-
cle injury was caused by intramuscular injection of cardiotoxin in the Tibialis Anterior (TA) muscle, as previously described (Mounier
et al., 2013). Fib-mdx was realized as previously described (Desguerre et al., 2012) and mice were studied one week after the last
injuries.
Cells
Mouse cell line
NIH 3T3 cells were cultured in DMEM Glutamax (GIBCO) containing 15% Fetal Bovine Serum (FBS) (GIBCO).
Primary Mouse cells: Bone Marrow Derived Macrophages (BMDM).
Total mouse bone marrow was obtained by flushing femur and tibiae with DMEM and cells were cultured in DMEM containing 20%
Fetal Bovine Serum (FBS) and 30% of L929 cell line-derived conditioned medium (enriched in CSF-1) for 6-7 days.
Primary Mouse cells: freshly FACS-isolated macrophages
Macrophages were isolated from skeletal TA muscle and directly used for coculture experiments (see below).
Primary Human cells: fibroblasts from human muscle
were obtained fromDMDor non-DMDpatients, as described in (Desguerre et al., 2009) fromCochin Hospital Cell Bank, Paris, agree-
ment no. DC-2009-944.
Human muscle
Muscle biopsies from 6 patients with DMD, whose diagnosis was established based on a total absence of dystrophin (negative Dys1,
Dys2, and Dys3 by immunohistochemistry and confirmed by western blot), were used as in (Desguerre et al., 2009).Cell Reports 25, 2163–2176.e1–e6, November 20, 2018 e3
METHOD DETAILS
Mice experiments
Mice treatments
Metformin (Sigma) was added in the drinking water (200 mg/kg/day, i.e., 1 mg/ml, replaced every day) during the 2 weeks of fibrosis
establishment in the fib-mdx model and for further 1.5 week. MMP14 inhibitor (NSC-405020, MedChemExpress) and BMP1 inhibitor
(UK-383367, Sigma-Aldrich) were solubilized in PBS containing 5% DMSO and were injected (i.p., 10 mg/kg for NSC-405020 and
4 mg/kg for UK-383367) every 3 days during the 2 weeks of fibrosis establishment in the fib-mdx model and for 1 more week.
In vivo isometric force measurement
Mice were maintained under isoflurane anesthesia. A small transverse incision was made above the right malleoli in order to expose
all the tendons surrounding the ankle joint. All the tendons except that of TAmuscle were severed to specifically assess the isometric
force produced by this muscle. Skin incision was closed using 5/0 polyester fiber suture. Each mouse was then placed supine in a
cradle allowing for a standardization of the animal positioning. The right foot was positioned and firmly immobilized through a rigid
slipper on a pedal of an ergometer (NIMPHEA_Research, AII Biomedical SAS). The pedal of the ergometer was adjusted to position
the ankle joint at 20 of plantar flexion (where 0 corresponding to the pedal of the ergometer perpendicular to the tibia). The right knee
was also firmly maintained using a rigid fixation in order to optimize isometric force recordings. Two 27G needle electrodes (745 12-
100/24, Ambu Neuroline) were positioned subcutaneously on the proximal and distal parts of the TA. Monophasic rectangular
pulses of 0.2 ms were delivered using a constant-current stimulator (Digitimer DS7AH, Hertfordshire, UK; maximal voltage:
400 V). The force-frequency curves were determined by stepwise increasing stimulation frequency, with resting periods > 30 s be-
tween stimuli in order to avoid effects due to fatigue. Force signal was sampled at 1000 Hz using a Powerlab system and Labchart
software (ADinstruments).
Histology and immunofluorescence analyses
Mouse
Fascia of TA muscles was removed, then muscles were frozen in nitrogen-chilled isopentane and kept at80C until use. 8 mm-thick
cryosections were prepared for hematoxylin-eosin (HE), masson trichrome (MT) and immunolabelings. For double immunolabelings,
cryosections were labeled with antibodies (from Abcam unless indicated) against F4/80 (ab6640, ab74383) overnight at 4C and la-
beling using the second antibodywas performed for 2 h at 37C. Antibodies were directed against Arginase 1 (sc-18355, Santa Cruz),
CCL3 (ab32609), CCR2 (ab32144), CD206 (sc-58987, Santa Cruz), CD301 (ab59167), Collagen I (ab292, ab34710 or Biotech
131001), Cox2 (ab23672), Dectin 1 (ab53427), IL-10 (ab9969), iNOS (ab15323), Laminin (L9393, sigma aldrich, or ab78287), PDGFRa
(AF1062, R&D System), TNFa (ab34839), LTBP4 (sc-33144, Santa Cruz), MMP14 (ab51074) and BMP1 (ab118520). Secondary an-
tibodies were coupled to FITC, Cy3 or Cy5 (Jackson Immunoresearch Inc). Muscle stem cells were immunolabeled with an antibody
directed against Pax7 as previously described (Theret et al., 2017).
Human
Serial muscle sections were immunolabelled as described above using the following antibodies CD68 (ab955), Myogenin (Develop-
mental Studies Hybridoma Bank, DSHB F5D), eMHC (DSHB F1.652), Collagen 1 (Southern Biotech), CD163 (sc-20066), CD206
(ab64693), Arg1 (sc-18355), iNOS (ab15323), TNFa (ab6671) and revealed with Cy3- and FITC- conjugated secondary antibodies
(antibody combinations are shown in Table S1).
FACS experiments
Isolation of macrophages from skeletal muscle
Fascia of the TA muscles was removed. Muscles were dissociated and digested in RPMI medium containing collagenase B 2 mg/ml
(Roche Diagnostics GmbH) at 37C for 1h (2h for fibrotic muscle) and passed through a 30 mm cell strainer (Miltenyi Biotec). CD45pos
cells were isolated using magnetic sorting (Miltenyi Biotec) and incubated with anti-mouse FcgRII/III (2.4G2) for 20 min at 4C in PBS
2% FBS. Cells were then stained with APC-conjugated anti-Ly6C/G or anti-Ly6C antibodies (eBioscience) and/or CD64 (BD
PharMingen 558539) for 30 min at 4C.Macrophages were analyzed with a Fortessa flow cytometer (BD Biosciences) or were sorted
using a FACS Aria III cell sorter (BD Biosciences). Analyses of immune cell population were done using antibodies against CD11b,
CD3, CD11c, Mgl1, Ly6C, LyC6G, NK1.1 (BD biosciences) and F4/80 (ebiosciences) (gating strategy is shown Figure S1).
Isolation of all cell populations from skeletal muscle
TA muscles were dissociated and digested in DMEM F/12 medium (GIBCO) containing 10 mg/ml of collagenase B and 2.4 U/ml
Dispase (Roche Diagnostics GmBH) at 37C for 30 min (1h for fibrotic muscles) and passed through a 30 mm cell strainer. CD45pos
and CD45neg were separated using magnetic beads. CD45pos cells were incubated with anti-mouse FcgRII/III (2.4G2) for 20 min at
4C in PBS 2%FBS and stained with PE-Cy7-conjugated anti-CD45 (25-0451-82, eBioscience) and APC-conjugated anti-Ly6C anti-
body (17-5932-82, eBioscience) for 30 min at 4C. CD45neg cells were stained with PE-Cy7-conjugated anti-CD45, PerCP-Cy5.5-
conjugated anti-Sca-1 (45-5981-82, eBioscience), Alexa Fluor 647-conjugated anti-a7-integrin (AB0000538, AB lab, University
British Columbia), PE-conjugated anti-CD31 (12-0311-82, eBioscience) and FITC-conjugated anti-CD34 (11-0341-82, eBioscience)
antibodies for 30 min at 4C. Cells were sorted using a FACS Aria II cell sorter (BD Biosciences). Flow cytometry plots and gating
strategy are provided in Figure S6A and S6B.e4 Cell Reports 25, 2163–2176.e1–e6, November 20, 2018
Cell culture
Bone Marrow Derived Macrophages (BMDM).
Total mouse bone marrow was obtained by flushing femur and tibiae with DMEM and cells were cultured in DMEM containing 20%
Fetal Bovine Serum (FBS) and 30% of L929 cell line-derived conditioned medium (enriched in CSF-1) for 6-7 days. Macrophages
were polarized toward various inflammatory states using 50 ng/ml IFNg (M1), 10 ng/ml IL4 (M2a) or 1 mg/ml of total protein lysate
from Fib-mdx muscle, in DMEM containing 10% FBS for 3 days. In some experiments, DMSO, 10 mM991 (SpiroChem) or 1 mMMet-
formin was added to the culture medium for the last 20 h. When required, control siRNAs (AllStars Negative Control siRNA, QIAGEN)
or siRNAs directed against ltbp4 (GeneSolution siRNA, QIAGEN) were transfected into BMDM (10 nM final concentration) using jet-
PRIME (Polyplus transfection) for 4-6 hours. Medium was then washed with PBS and transfected BMDM were polarized as
described above.
Coculture of macrophages with fibroblasts
NIH 3T3 cells were cultured in DMEMGlutamax (GIBCO) containing 15%Fetal Bovine Serum (FBS) (GIBCO). For the Collagen-1 lucif-
erase assay, NIH 3T3 were seeded at 28000 cells/cm2 in 96 well-plates. The next day, cells were co-transfected with Lipofectamine
2000 (Promega) and incubated with 1.6 mg of pGl3-Collagen I plasmid (luciferase under the collagen I promoter, a generous gift of
Peter Mertens, Otto-von-Guericke-Universita¨t Magdeburg, Germany) or pGl3-control plasmid. In some experiments, NIH 3T3 cells
were co-transfected with pGL3-Collagen I (0.5 mg), 0.5 mg of pRL-TK (0.5 mg) (Renilla Luciferase Control Reporter Vectors, Promega)
and 10 nM of control siRNAs (AllStars Negative Control siRNA, QIAGEN) or siRNAs directed againstmmp14 or bmp1 (GeneSolution
siRNA, QIAGEN) using Jetprime (Polyplus transfection) for 4h. Mediumwas removed and cells were cocultured overnight with sorted
macrophages (14000 cell/cm2) in DMEM Glutamax containing 1% FBS. Cocultures were rinsed with PBS and cells were processed
for Dual-Glo Luciferase Assay System (Promega) and quantified with a Luminometer. For the analysis of proliferation, differentiation
and apoptosis of fibroblasts, NIH 3T3 cells were seeded at 10000 cells/cm2 in 96 well-plates and cocultured overnight with sorted
macrophages (10000 cells/cm2) in DMEMGlutamax containing 1% FBS. In some experiments, blocking anti-TGFb1 antibodies were
added (1/200, Abcam 64715). Cocultures were then fixed and immunolabelled with antibodies against a-SMA (sigma A5228), Ki67
(ab15580) or active Caspase 3 (ab13847), revealed with Cy3- conjugated secondary antibodies. For each condition of each exper-
iment, about 6-10 fields chosen randomly were recorded with a DMI 6000 Leicamicroscope connected to a Coolsnap camera at 20X
magnification.
Molecular biology
TGFb1 quantitation.
50000 BMDMwere seeded in 96-well plates and polarized as described above. They were then washed twice with PBS and cultured
in DMEM containing 0.1% BSA for 20 h. Sorted macrophages from fibrotic or regenerating muscle were directly collected in DMEM
containing 0.1%BSA and cultured for 20 h. Conditionedmediumwas then harvested and centrifuged for 5min at 2000 rpm. One part
of the sample was used directly to determine the level of active TGFb1 by ELISA (TGF beta-1 Human/Mouse Uncoated ELISA Kit,
Invitrogen). To measure the level of total TGFb1, the other part of the sample was subjected to heat denaturation followed by acidic
treatment and neutralization according to the manufacturer’s instructions.
qRT-PCR
Mouse BMDMand human fibroblasts (obtained fromDMDor non-DMDpatients, as described in (Desguerre et al., 2009) fromCochin
Hospital Cell Bank, Paris, agreement no. DC-2009-944) were lyzed with TRIzol reagent (Life Technologies) and total RNAs were
separated from proteins and DNA with addition of chloroform. Sorted cells were collected in RLT+ Buffer (QIAGEN) and total
RNAs were isolated using RNeasy Plus Micro kit (QIAGEN). RNAs were retro-transcribed into cDNA using Superscript II Reverse
Transcriptase and qPCRwas carried out in triplicate on aCFXConnectTM Real-Time PCRDetection System (Bio-Rad). Reactionmix-
tures had a final volume of 10 ml, consisting of 2 ml of cDNA, 5 ml of LightCycler 480 SYBR Green I Master and 0.5 mM primers. After
initial denaturation, amplification was performed at 95C (10 s), 60C (5 s) and 72C (10 s) for 45 cycles. Calculation of relative expres-
sion was determined by the Bio-Rad CFX ManagerTM software and fold change was normalized as Normalized Relative Quantity (or
DDCq) for each series, asNRQ=
2DCqTCqCal
2DCqRCqCal
where T is the target sample, Cal the calibrator value (i.e., the mean of all sample Cqs of
the serie) and R is the housekeeping gene Cyclophilin A for mouse or Ap3d1 for human. Log2-NRQ values were used to perform sta-
tistical analyses. Primer details are presented in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mouse histology
HE-stained muscle sections were recorded with a Nikon E800 microscope at 20X magnification connected to a QIMAGING camera.
Necrotic myofibers were defined as pink pale patchy fibers, phagocytedmyofibers were defined as pink pale fibers invaded by baso-
philic single cells (macrophages). Fluorescent immunolabelings were recorded with a DMI 6000 Leica microscope connected to a
Coolsnap camera at 20X magnification. For confocal analysis, pictures were taken on a TCS SP5 X microscope (Leica Microsys-
tems). For each condition of each experiment, at least 8-10 fields chosen randomly were counted. The number of labeledCell Reports 25, 2163–2176.e1–e6, November 20, 2018 e5
macrophages was calculated using the cell tracker in ImageJ software and expressed as a percentage of total macrophages. Areas
(PDGFR-a, Collagen 1) were calculated with ImageJ software. Amacro was designed in ImageJ software to identify clusters contain-
ing small (< 200 mm2) and large (> 200 mm2) myofibers. The number of macrophages per fiber was counted in these areas defined
using this macro (Figure S2). TGFb1 mean fluorescence intensity (MFI) was measured using ImageJ. First, a mask was generated
using either TGFb1 or F4/80 labeling to select the areas of TGFb1 or F4/80 expression. TGFb1 MFI was then measured in both areas
and the ratio of TGFb1 MFI in F4/80 areas/ total TGFb1 MFI was calculated.
Human histology
Analysis was performed for individual fascicles, which are easy to circumscribe. About 25-30 fascicles were analyzed. The number of
cells was normalized for 100 myofibers.
Statistical Analyses
All experiments were performed using at least three different cultures or animals in independent experiments. The Student’s t test,
ANOVA or Spearman correlation test were used for statistical analyses. p < 0.05 was considered significant.e6 Cell Reports 25, 2163–2176.e1–e6, November 20, 2018
